Stellar Biotechnologies' Announces Effective Date of TSX-V

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stellar Biotechnologies' Announces Effective Date of TSX-V Voluntary Delisting

PORT HUENEME, CA--(Marketwired - Mar 29, 2016) - Stellar Biotechnologies, Inc. ("Stellar") ( NASDAQ : SBOT ) ( TSX VENTURE : KLH ), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin, today announced that the Company's voluntary delisting from the TSX Venture Exchange ("TSX-V") will be effective at the close of business April 8, 2016 (the "Effective Date"). 

Following the Effective Date, all of Stellar's common shares (the "Shares") will continue to be listed and to trade on The Nasdaq Capital Market under the Company's symbol "SBOT."

For additional information regarding the Company's Voluntary Delisting for TSX-V, please visit http://ir.stellarbiotechnologies.com/tsx-v-vo...isting-faq or contact Stellar's Investor Relations at ir@stellarbiotech.com .

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. ( NASDAQ : SBOT ) ( TSX VENTURE : KLH ) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org .

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; liquidity of the Company's shares on Nasdaq; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with U.S., Canadian or other governmental regulations; the timing of the Company's or its partners' anticipated results, including in connection with clinical trials; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the B.C. Securities Commission and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

Stellar Biotechnologies Company Contact: Mark A. McPartland Vice President of Corporate Development and Communications Phone: +1 (805) 488-2800 ext. 103 markmcp@stellarbiotech.com www.stellarbiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 49

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 205

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 113

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 68

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 89

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 19

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 142

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading

Top 5 Most Recently Viewed Articles

RAMM Pharma Corp. Strategizes Potential Sale of Canapar

Updated Category News Views 184

RAMM Pharma Corp. Explores Strategic Sale Options RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry....

Continue Reading
Marquis Software Solutions Faces Major Data Breach Issues

Updated Category News Views 206

Marquis Software Solutions Faces Data Breach Concerns Recently, Marquis Software Solutions, a notable software and services provider, faced a serious incident regarding a data breach that may have compromised the personal information of many individuals. This breach raised significant concerns for anyone whose data might have been affected. Details of the Cybersecurity...

Continue Reading
Recovering Losses: GSK Securities Class Action Explained

Updated Category News Views 192

Understanding the GSK Securities Class Action Lawsuit Investors in GSK plc (NYSE: GSK) now find themselves presented with a significant opportunity to participate in a class action lawsuit. This legal action is initiated on behalf of purchasers of American Depositary Receipts (ADRs) from a defined Class Period. The relevant dates for this lawsuit span from early in 2020...

Continue Reading
CYPFER and Michael Bay Team Up for Cybersecurity Advancements

Updated Category News Views 366

Strengthening Cybersecurity in Entertainment with CYPFER In an era where digital security is paramount, CYPFER is leading the charge to develop comprehensive cybersecurity strategies tailored for the film and entertainment industry. The company has formed a partnership with iconic filmmaker Michael Bay, known for his blockbuster hits that captivate audiences worldwide....

Continue Reading
Chris Hall Appointed as CPO of IRIS Software Group

Updated Category News Views 108

Chris Hall Steps in as Chief Product Officer at IRIS Software Group Pivotal leadership appointment will accelerate product innovation and delivery of AI-first strategy IRIS Software Group, a renowned global provider of accounting, HR, payroll, and education software, has announced a significant enhancement to its leadership team with the appointment of Chris Hall as Chief...

Continue Reading